Atea Pharmaceuticals, Inc. — All Filings
294 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
144
3
4
4/A
424B4
8-A12B
8-K
ARS
CERT
CORRESP
D
D/A
DEF 14A
DEFA14A
DFAN14A
DRS
DRS/A
DRSLTR
EFFECT
POS AM
POSASR
S-1
S-1/A
S-1MEF
S-3
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13D
SCHEDULE 13D/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| SC 13G/A | — | 0000935836-24-000228 | Feb 14, 2024 | — |
| SC 13G/A | — | 0000935836-24-000226 | Feb 14, 2024 | — |
| SC 13G/A | SC 13G/A | 0001193125-24-033799 | Feb 13, 2024 | — |
| SC 13G/A | SCHEDULE 13G/A | 0001104659-24-020352 | Feb 13, 2024 | — |
| SC 13G/A | — | 0000315066-24-000968 | Feb 9, 2024 | — |
| SC 13G/A | — | 0001616824-24-000017 | Feb 7, 2024 | — |
| SC 13G | — | 0001616824-24-000015 | Feb 7, 2024 | — |
| 4 | 4 | 0000950170-24-010967 | Feb 2, 2024 | Jan 31, 2024 |
| 4 | 4 | 0000950170-24-010973 | Feb 2, 2024 | Jan 31, 2024 |
| 4 | 4 | 0000950170-24-010972 | Feb 2, 2024 | Jan 31, 2024 |
| 4 | 4 | 0000950170-24-010970 | Feb 2, 2024 | Jan 31, 2024 |
| 4 | 4 | 0000950170-24-010969 | Feb 2, 2024 | Jan 31, 2024 |
| 4 | 4 | 0000950170-24-010968 | Feb 2, 2024 | Jan 31, 2024 |
| 144 | — | 0000950170-24-009803 | Feb 1, 2024 | — |
| 144 | — | 0000950170-24-009802 | Feb 1, 2024 | — |
| 144 | — | 0000950170-24-009801 | Feb 1, 2024 | — |
| 144 | — | 0000950170-24-009800 | Feb 1, 2024 | — |
| 144 | — | 0000950170-24-009799 | Feb 1, 2024 | — |
| 144 | — | 0000950170-24-009804 | Feb 1, 2024 | — |
| SC 13G/A | — | 0001086364-24-002027 | Jan 24, 2024 | — |
| SC 13D/A | AMENDMENT NO. 1 | 0001214659-23-015585 | Nov 28, 2023 | — |
| 8-K | 8-K | 0001193125-23-273532 | Nov 8, 2023 | — |
| 10-Q | 10-Q | 0000950170-23-061213 | Nov 8, 2023 | Sep 30, 2023 |
| SC 13G/A | — | 0001306550-23-010280 | Nov 7, 2023 | — |
| SC 13G | — | 0001616824-23-000007 | Oct 2, 2023 | — |
| SC 13G/A | — | 0000315066-23-002589 | Sep 11, 2023 | — |
| 8-K | 8-K | 0001193125-23-206247 | Aug 8, 2023 | — |
| 10-Q | 10-Q | 0000950170-23-039920 | Aug 8, 2023 | Jun 30, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016129 | Jun 21, 2023 | Jun 16, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016128 | Jun 21, 2023 | Jun 16, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016131 | Jun 21, 2023 | Jun 16, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016126 | Jun 21, 2023 | Jun 16, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016130 | Jun 21, 2023 | Jun 16, 2023 |
| 4 | FORM 4 SUBMISSION | 0000899243-23-016127 | Jun 21, 2023 | Jun 16, 2023 |
| 8-K | 8-K | 0001193125-23-171257 | Jun 21, 2023 | Jun 16, 2023 |
| DEFA14A | DEFA14A | 0000950170-23-027367 | Jun 12, 2023 | — |
| DEFA14A | DEFA14A | 0000950170-23-024297 | May 25, 2023 | — |
| SC 13D | — | 0001214659-23-007616 | May 22, 2023 | — |
| 8-K | 8-K | 0001193125-23-138257 | May 8, 2023 | — |
| 10-Q | 10-Q | 0000950170-23-018869 | May 8, 2023 | Mar 31, 2023 |
| DEFA14A | DEFA14A | 0000950170-23-015810 | Apr 28, 2023 | — |
| ARS | ARS | 0000950170-23-015921 | Apr 28, 2023 | Dec 31, 2022 |
| DEF 14A | DEF 14A | 0000950170-23-015773 | Apr 28, 2023 | — |
| 8-K | 8-K | 0001193125-23-053843 | Feb 28, 2023 | — |
| 10-K | 10-K | 0000950170-23-005186 | Feb 28, 2023 | Dec 31, 2022 |
| SC 13G/A | — | 0000935836-23-000099 | Feb 10, 2023 | — |
| SC 13G/A | SC 13G/A | 0001193125-23-032602 | Feb 10, 2023 | — |
| SC 13G/A | — | 0000315066-23-001421 | Feb 9, 2023 | — |
| SC 13G/A | SCHEDULE 13G/A | 0001104659-23-015377 | Feb 9, 2023 | — |
| 4 | FORM 4 SUBMISSION | 0000899243-23-003615 | Feb 2, 2023 | Jan 31, 2023 |